69 related articles for article (PubMed ID: 9717833)
21. Levels of circulating regulatory CD4+CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine.
Hueman MT; Stojadinovic A; Storrer CE; Foley RJ; Gurney JM; Shriver CD; Ponniah S; Peoples GE
Breast Cancer Res Treat; 2006 Jul; 98(1):17-29. PubMed ID: 16758122
[TBL] [Abstract][Full Text] [Related]
22. MUC1-derived glycopeptide libraries with improved MHC anchors are strong antigens and prime mouse T cells for proliferative responses to lysates of human breast cancer tissue.
Gad M; Jensen T; Gagne R; Komba S; Daugaard S; Kroman N; Meldal M; Werdelin O
Eur J Immunol; 2003 Jun; 33(6):1624-32. PubMed ID: 12778480
[TBL] [Abstract][Full Text] [Related]
23. Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells.
Kobayashi H; Nagato T; Takahara M; Sato K; Kimura S; Aoki N; Azumi M; Tateno M; Harabuchi Y; Celis E
Cancer Res; 2008 Feb; 68(3):901-8. PubMed ID: 18245493
[TBL] [Abstract][Full Text] [Related]
24. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
[TBL] [Abstract][Full Text] [Related]
25. Identification of T helper epitopes from prostatic acid phosphatase.
McNeel DG; Nguyen LD; Disis ML
Cancer Res; 2001 Jul; 61(13):5161-7. PubMed ID: 11431355
[TBL] [Abstract][Full Text] [Related]
26. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
[TBL] [Abstract][Full Text] [Related]
27. Vaccination strategy determines the emergence and dominance of CD8+ T-cell epitopes in a FVB/N rat HER-2/neu mouse model of breast cancer.
Singh R; Paterson Y
Cancer Res; 2006 Aug; 66(15):7748-57. PubMed ID: 16885378
[TBL] [Abstract][Full Text] [Related]
28. Characterization of B- and T-cell responses and HLA-DR4 binding motifs of the latex allergen Hev b 6.01 (prohevein) and its post-transcriptionally formed proteins Hev b 6.02 and Hev b 6.03.
Raulf-Heimsoth M; Rozynek P; Brüning T; Rihs HP
Allergy; 2004 Jul; 59(7):724-33. PubMed ID: 15180759
[TBL] [Abstract][Full Text] [Related]
29. The shaping of a polyvalent and highly individual T-cell repertoire in the bone marrow of breast cancer patients.
Sommerfeldt N; Schütz F; Sohn C; Förster J; Schirrmacher V; Beckhove P
Cancer Res; 2006 Aug; 66(16):8258-65. PubMed ID: 16912206
[TBL] [Abstract][Full Text] [Related]
30. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer.
Chianese-Bullock KA; Irvin WP; Petroni GR; Murphy C; Smolkin M; Olson WC; Coleman E; Boerner SA; Nail CJ; Neese PY; Yuan A; Hogan KT; Slingluff CL
J Immunother; 2008 May; 31(4):420-30. PubMed ID: 18391753
[TBL] [Abstract][Full Text] [Related]
31. Axillary lymph node cellular immune response to HER-2/neu peptides in patients with carcinoma of the breast.
Kuerer HM; Peoples GE; Sahin AA; Murray JL; Singletary SE; Castilleja A; Hunt KK; Gershenson DM; Ioannides CG
J Interferon Cytokine Res; 2002 May; 22(5):583-92. PubMed ID: 12060497
[TBL] [Abstract][Full Text] [Related]
32. Identification of HLA class II H5N1 hemagglutinin epitopes following subvirion influenza A (H5N1) vaccination.
Zinckgraf JW; Sposato M; Zielinski V; Powell D; Treanor JJ; von Hofe E
Vaccine; 2009 Aug; 27(39):5393-401. PubMed ID: 19596415
[TBL] [Abstract][Full Text] [Related]
33. Identification of HLA-DRB1*1501-restricted T-cell epitopes from prostate-specific antigen.
Klyushnenkova EN; Link J; Oberle WT; Kodak J; Rich C; Vandenbark AA; Alexander RB
Clin Cancer Res; 2005 Apr; 11(8):2853-61. PubMed ID: 15837732
[TBL] [Abstract][Full Text] [Related]
34. Fine specificity of high molecular weight-melanoma-associated antigen-specific cytotoxic T lymphocytes elicited by anti-idiotypic monoclonal antibodies in patients with melanoma.
Murray JL; Gillogly M; Kawano K; Efferson CL; Lee JE; Ross M; Wang X; Ferrone S; Ioannides CG
Cancer Res; 2004 Aug; 64(15):5481-8. PubMed ID: 15289358
[TBL] [Abstract][Full Text] [Related]
35. Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide.
Gates JD; Clifton GT; Benavides LC; Sears AK; Carmichael MG; Hueman MT; Holmes JP; Jama YH; Mursal M; Zacharia A; Ciano K; Khoo S; Stojadinovic A; Ponniah S; Peoples GE
Vaccine; 2010 Nov; 28(47):7476-82. PubMed ID: 20858449
[TBL] [Abstract][Full Text] [Related]
36. Does pregnancy immunize against breast cancer?
Agrawal B; Reddish MA; Krantz MJ; Longenecker BM
Cancer Res; 1995 Jun; 55(11):2257-61. PubMed ID: 7538899
[TBL] [Abstract][Full Text] [Related]
37. A CD80-transfected human breast cancer cell variant induces HER-2/neu-specific T cells in HLA-A*02-matched situations in vitro as well as in vivo.
Gückel B; Stumm S; Rentzsch C; Marmé A; Mannhardt G; Wallwiener D
Cancer Immunol Immunother; 2005 Feb; 54(2):129-40. PubMed ID: 15365776
[TBL] [Abstract][Full Text] [Related]
38. Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer.
Gillogly ME; Kallinteris NL; Xu M; Gulfo JV; Humphreys RE; Murray JL
Cancer Immunol Immunother; 2004 Jun; 53(6):490-6. PubMed ID: 14740174
[TBL] [Abstract][Full Text] [Related]
39. HER-2/neu-derived peptide 884-899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4(+) T cell clones.
Perez SA; Sotiropoulou PA; Sotiriadou NN; Mamalaki A; Gritzapis AD; Echner H; Voelter W; Pawelec G; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2002 Jan; 50(11):615-24. PubMed ID: 11807625
[TBL] [Abstract][Full Text] [Related]
40. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients.
Knutson KL; Schiffman K; Disis ML
J Clin Invest; 2001 Feb; 107(4):477-84. PubMed ID: 11181647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
